Addendum
Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31
Report documents
-
Addendum
Avatrombopag (thrombocytopenia) - Addendum to Commission A21-31
Dossier assessment
Indication:
Adult patients with severe thrombocytopenia and chronic liver disease who are scheduled to undergo an invasive procedure
Result of dossier assessment:
Unchanged after addendum:
- Moderate or high bleeding risk of the invasive procedure: proof of considerable added benefit.
- Low bleeding risk of the invasive procedure: added benefit not proven.
Additional information
Federal Joint Committee (G-BA)
2021-09-16 A G-BA decision was published.
Project details
- Project no.
- A21-103
- Commission
- Commission awarded on 10.08.2021 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
If the need for additional work on a project commissioned by the GBA arises during consultations, IQWiG submits an addendum. The subsequent decides on the extent of the added benefit concludes the early benefit assessment.
Connected Projects
-
Dossier assessment
Avatrombopag (thrombocytopenia) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed